Abstract: The disclosure discloses a fatty acid synthase inhibitor and application thereof and belongs to the technical field of medical biology. The fatty acid synthase inhibitor of the disclosure can significantly inhibit the activity of fatty acid synthase without affecting normal expression, and adjust the ratio of fatty acids in cells. The fatty acid synthase inhibitor of the disclosure has a good tumor proliferation inhibitory effect, can arrest the growth cycle of tumor cells in the interphase, prevent tumor cell division, inhibit tumor cell proliferation, promote tumor cell apoptosis and exert a tumor treatment effect, can be used to treat tumors and metabolism related diseases, and has an important clinical application prospect.

Abstract: The invention provides a fusion protein for treating metabolic diseases, and a preparation method and use thereof. The fusion protein has a general formula of R1-L-R2 or R2-L-R1, wherein R1 is FGF21 protein, an FGF21 protein analog, or a similar peptide with the biological function of FGF21 protein; R2 is GIP, mutant GIP or a similar peptide with the biological function of GIP; and L is a linker peptide. The fusion protein of the present invention is used as a therapeutic agent or a pharmaceutical composition in the treatment of diseases associated with hyperglycemia and hyperlipidemia, including diabetes, obesity, steatohepatitis or cardiovascular diseases, with a therapeutic effect significantly better than that of original FGF21 and GIP.

Abstract: The present disclosure discloses a preparation method and use of a double-target fusion protein, and belongs to the technical field of medicines. According to the present disclosure, a novel fusion protein is obtained by transforming an FGF19 sequence and fusing the FGF19 sequence with GLP-1. Compared with wild-type FGF19 and GLP-1, the novel fusion protein has a more long-acting and stable effect, further reduces the carcinogenic risk of FGF19, and can better relieve liver damage and correct metabolic disorder, obesity, overweight, metabolic syndrome, diabetes, dyslipidemia and other diseases. Besides, in treatment, there are no side effects of gastrointestinal discomforts such as diet decline caused by GLP-1 treatment. Therefore, the double-target fusion protein has a wide application prospect.

Abstract: The present disclosure discloses a preparation method and use of a double-target fusion protein, and belongs to the technical field of medicines. According to the present disclosure, a novel fusion protein is obtained by transforming an FGF19 sequence and fusing the FGF19 sequence with GLP-1. Compared with wild-type FGF19 and GLP-1, the novel fusion protein has a more long-acting and stable effect, further reduces the carcinogenic risk of FGF19, and can better relieve liver damage and correct metabolic disorder, obesity, overweight, metabolic syndrome, diabetes, dyslipidemia and other diseases. Besides, in treatment, there are no side effects of gastrointestinal discomforts such as diet decline caused by GLP-1 treatment. Therefore, the double-target fusion protein has a wide application prospect.

Abstract: The disclosure discloses a new anti-metabolic disorder FGF analog and an application thereof, and belongs to the technical field of medicines. According to the disclosure, modification is performed based on an FGF19 mutant NGM282 to obtain a new FGF19 analog, which has the effects of being more long-acting and stable compared with NGM282, can better ameliorate liver impairment and correct diseases such as metabolic disorders, obesity, overweight, metabolic syndrome, diabetes and dyslipidemia and has no side effects of elevated cholesterol and dietary decline caused by the original FGF19 mutant NGM282 in a therapeutic process.

Abstract: Disclosed is an application of Stachyose in preparation of a drug for treating castration-resistant prostate cancer, belonging to the technical field of biological medicine. The disclosure proposes a new strategy of using Stachyose in combination with an androgen receptor antagonist to prepare a drug for treating CRPC for the first time, and conducts multi-angle and multi-level verification research. The drug composition of the Stachyose in combination with the androgen receptor in the disclosure can be used for treating castration-resistant prostate cancer, and significantly improves the effect of Enzalutamide on inhibiting castration-resistant prostate cancer. The natural compound is applied to the advanced stage of cancer, and has important clinical therapeutic significance.

Abstract: The present disclosure discloses use of polaprezinc (Pola) in preparing a drug for treating castration-resistant prostate cancer (CRPC) and belongs to the technical field of biological medicine. The present disclosure provides a new strategy for preparing the drug for treating the CRPC by combining the Pola with an androgen receptor antagonist for the first time and conducts a multi-angle and multi-level verification research. A drug composition combining the polaprezinc and the androgen receptor antagonist can be used for treating castration-resistant prostate cancer, remarkably improves an effect of enzalutamide in inhibiting the castration-resistant prostate cancer, realizes new use of the old drug, can greatly shorten time from drug discovery to clinical transformation, and has important clinical treatment significance.

Abstract: The present disclosure discloses application of D. newyorkensis in prolonging lifespan and anti-aging, and belongs to the technical fields of biomedicine and microorganisms. The D. newyorkensis NYU-BL-A4 used in the present disclosure can prolong the lifespan of C. elegans without affecting the normal vital sign of swallowing frequency of C. elegans, is safe and has no toxic and side effects to the nematodes. Therefore, it can have a good anti-aging effect and can be applied to the preparation of anti-aging and life-prolonging products.

Abstract: The present invention discloses application of FGF21 in the preparation of medicines for treating colorectal cancer, and belongs to the technical field of medicine. The FGF21 protein provided by the present invention is a secreted protein composed of about 210 amino acids. The present invention found that FGF21 has the effect of treating colorectal tumors for the first time. It is proved by cytology and animal experiments that FGF21 can inhibit the proliferation, invasion and migration of colorectal tumor cell lines; can significantly reduce the size of tumor lesions in mouse models. The medicines prepared from FGF21 as the active ingredient for treating colorectal cancer has good safety and long duration of drug action, while it protects organs from damage and has the effect of improving lipid metabolism disorders.

Abstract: The disclosure discloses a fatty acid synthase inhibitor and application thereof and belongs to the technical field of medical biology. The fatty acid synthase inhibitor of the disclosure can significantly inhibit the activity of fatty acid synthase without affecting normal expression, and adjust the ratio of fatty acids in cells. The fatty acid synthase inhibitor of the disclosure has a good tumor proliferation inhibitory effect, can arrest the growth cycle of tumor cells in the interphase, prevent tumor cell division, inhibit tumor cell proliferation, promote tumor cell apoptosis and exert a tumor treatment effect, can be used to treat tumors and metabolism related diseases, and has an important clinical application prospect.

Abstract: The present invention provides a surface alloy coating composite material for a high temperature resistant material, a coating and a manufacturing method thereof, wherein the surface alloy coating composite material is made of metal alloy powder having a face-centered cubic structure and enamel powder, and a component percentage thereof is as follows: 10-70 wt % is the metal alloy powder, and remaining is the enamel powder; the metal alloy powder is selected from at least one type of NiCrAIX, NiCrX and NiCoCrAIX, wherein X is at least one type of hafnium, zirconium, a rare earth element and mixed rare earth, and the mixed rare earth can be two types or more than two types of rare earth elements that are used together or a rare earth element and one type or multiple types of Na, K, Ca, Sr and Ba that are used in a combined way.

Abstract: The present invention provides a surface alloy coating composite material for a high temperature resistant material, a coating and a manufacturing method thereof, wherein the surface alloy coating composite material is made of metal alloy powder having a face-centered cubic structure and enamel powder, and a component percentage thereof is as follows: 10-70wt % is the metal alloy powder, and remaining is the enamel powder; the metal alloy powder is selected from at least one type of NiCrAIX, NiCrX and NiCoCrAIX, wherein X is at least one type of hafnium, zirconium, a rare earth element and mixed rare earth, and the mixed rare earth can be two types or more than two types of rare earth elements that are used together or a rare earth element and one type or multiple types of Na, K, Ca, Sr and Ba that are used in a combined way.